A Safety and Efficacy Study of FCR001 vs Standard of Care in de Novo Living Donor Kidney Transplantation

Stopped early · Phase 3

Conditions studied: Transplanted Organ Rejection

In brief

A randomized controlled study to evaluate the safety, efficacy, and overall benefit of FCR001 cell therapy in de novo living donor renal transplantation.

Key facts

Study ID
NCT03995901
Run by
Talaris Therapeutics Inc.
People needed
15
Starts
2019-10-25
Expected to finish
2023-02-16
Last updated by the study team
2023-03-03

Who can join

Age: 18 and older. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.